Boston Scientific Corp. Debt Rated 'BBB-'

NEW YORK (Standard&Poor's) April 16, 2015--Standard&Poor's Ratings Services today assigned its 'BBB-' issue-level ratings to Marlborough, Mass.-based medical device company Boston Scientific Corp.'s issuance of $750 million of senior unsecured term loan maturing in 2020 and a $250 million unsecured revolving credit facility maturing in 2015. The company will use these proceeds to fund the planned acquisition of Endo International PLC's Men's Health and Prostrate Health businesses and for general corporate purposes. The company is also amending covenants and extending the maturity on its $2 billion revolving credit facility, which will now mature in 2020. In addition, the company is amending terms on its $400 million unsecured term loan to include covenant terms that are consistent

...NEW YORK (Standard & Poor's) April 16, 2015--Standard & Poor's Ratings Services today assigned its '###-' issue-level ratings to Marlborough, Mass.-based medical device company Boston Scientific Corp.'s issuance of $750 million of senior unsecured term loan maturing in 2020 and a $250 million unsecured revolving credit facility maturing in 2015. The company will use these proceeds to fund the planned acquisition of Endo International PLC's Men's Health and Prostrate Health businesses and for general corporate purposes. The company is also amending covenants and extending the maturity on its $2 billion revolving credit facility, which will now mature in 2020. In addition, the company is amending terms on its $400 million unsecured term loan to include covenant terms that are consistent with its new 2015 credit agreement. We are also assigning our '###-' issue-level ratings to these obligations. Our '###-' corporate credit rating on Boston Scientific reflects our assessment of the company's...

Ratings Action